Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bianca D Santomasso

Showing results (11-20 of 42) with videos related to

Pageof 5
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|November 30, 2007
A T-cell receptor associated with naturally occurring human tumor immunityBianca D Santomasso, Wendy K Roberts, Ashby Thomas, et al.
Leukemia & Lymphoma|November 20, 2024
Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphomaXavier Deschênes-Simard, Martina Pennisi, Miguel-Angel Perales, et al.
European Journal of Immunology|August 9, 2014
T cells targeting a neuronal paraneoplastic antigen mediate tumor rejection and trigger CNS autoimmunity with humoral activationNathalie E Blachère, Dana E Orange, Bianca D Santomasso, et al.
JCI Insight|November 3, 2017
T cells presenting viral antigens or autoantigens induce cytotoxic T cell anergyNathalie E Blachère, Dana E Orange, Emily C Gantman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 15, 2021
Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse EventsJia Luo, Jason A Beattie, Paige Fuentes, et al.
Neuro-Oncology|October 18, 2019
MRI radiomic features are associated with survival in melanoma brain metastases treated with immune checkpoint inhibitorsAnkush Bhatia, Maxwell Birger, Harini Veeraraghavan, et al.
Cancer Immunology Research|May 23, 2019
BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential SynergyEric L Smith, Sham Mailankody, Mette Staehr, et al.
Blood Advances|July 3, 2020
DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortalityKitsada Wudhikarn, Martina Pennisi, Marta Garcia-Recio, et al.
Blood Cancer Journal|August 8, 2020
Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphomaKitsada Wudhikarn, M Lia Palomba, Martina Pennisi, et al.
Cancer Discovery|June 9, 2018
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic LeukemiaBianca D Santomasso, Jae H Park, Darin Salloum, et al.
Pageof 5

Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
Proceedings of the National Academy of Sciences of the United States of America|November 30, 2007
A T-cell receptor associated with naturally occurring human tumor immunityBianca D Santomasso, Wendy K Roberts, Ashby Thomas, et al.
Leukemia & Lymphoma|November 20, 2024
Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphomaXavier Deschênes-Simard, Martina Pennisi, Miguel-Angel Perales, et al.
European Journal of Immunology|August 9, 2014
T cells targeting a neuronal paraneoplastic antigen mediate tumor rejection and trigger CNS autoimmunity with humoral activationNathalie E Blachère, Dana E Orange, Bianca D Santomasso, et al.
JCI Insight|November 3, 2017
T cells presenting viral antigens or autoantigens induce cytotoxic T cell anergyNathalie E Blachère, Dana E Orange, Emily C Gantman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 15, 2021
Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse EventsJia Luo, Jason A Beattie, Paige Fuentes, et al.
Neuro-Oncology|October 18, 2019
MRI radiomic features are associated with survival in melanoma brain metastases treated with immune checkpoint inhibitorsAnkush Bhatia, Maxwell Birger, Harini Veeraraghavan, et al.
Cancer Immunology Research|May 23, 2019
BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential SynergyEric L Smith, Sham Mailankody, Mette Staehr, et al.
Blood Advances|July 3, 2020
DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortalityKitsada Wudhikarn, Martina Pennisi, Marta Garcia-Recio, et al.
Blood Cancer Journal|August 8, 2020
Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphomaKitsada Wudhikarn, M Lia Palomba, Martina Pennisi, et al.
Cancer Discovery|June 9, 2018
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic LeukemiaBianca D Santomasso, Jae H Park, Darin Salloum, et al.
Pageof 5